Uthever®︎ Clinical Study


A Leap Forward in NMN Research: Publication of Human Clinical Trial Data for Longevity Ingredient Uthever® NMN

Clinical Trial Registration: clinicaltrials.gov
US identifier: NCT04228640 NMN

Download Uthever® NMN Clinical Study

Amidst the burgeoning wealth of animal-focused scientific reports on Nicotinamide Mononucleotide (NMN), EffePharm has announced the publication of its Uthever® NMN research in the esteemed international journal on ageing mechanisms.

Having begun in 2020, the clinical trial revealed that as an endogenous compound, Uthever® NMN demonstrates safety and efficacy in enhancing NAD+/NADH levels within the human body, thereby facilitating its anti-ageing function. This groundbreaking human clinical trial, which began following successful animal tests, confirms NMN’s lack of acute toxicity.

The trial results, reviewed by prominent scientists, including professors from Harvard Medical School, were published in Frontiers in Ageing, a highly cited medical and pharmaceutical publication.

Results of the Uthever® NMN Clinical Trial

The aim of the clinical study is to investigate the safety and efficacy of Uthever® NMN, the first branded NMN ingredient. In addition, narrowing in on the anti-ageing impact of Uthever® NMN, it was assessed through parameters like pulse pressure and blood pressure normalisation.

For the safety evaluation, the study found no clinically significant safety concerns, with no adverse side effects observed. Beyond that, EffePharm’s clinical trial unveiled promising results as the Uthever® group displayed notable improvements in these parameters compared to the placebo group.

In terms of efficacy, the Uthever® group exhibited a trend of improvement in cellular blood NAD+/NADH, six-minute walking endurance, SF-36, and HOMA IR index compared to the placebo group.

1. Blood Cellular NAD+/NADH

Specifically, the Uthever® group showed an 11.3 percent increase in NAD+/NADH levels at day 30 and a remarkable 38 percent increase at day 60, compared to the placebo group’s 14.3 percent rise.

Uthever®(n=31) Placebo(n=31)
30 days 11.3% 0
60 days 38% 14.3%

Increasing proportion of NAD+/NADH

2. 6-Minute Walking Endurance Test

Walking endurance also demonstrated a positive effect, with a 6.5 percent increase in the Uthever® group at day 60, while the placebo group remained unchanged.

3. SF-36

Similarly, the SF-36 questionnaire, which serves as an indicator of subjects’ overall well-being, indicated enhanced well-being in the Uthever® group at day 60, showing almost double the increase compared to the placebo group.
side effects


The study also assessed the effects of Uthever® on insulin regulation. Parameters such as the HOMA IR index, fasting blood sugar, and serum insulin levels were evaluated. However, the HOMA IR index, fasting blood sugar, and serum insulin levels did not show statistically significant differences between the Uthever® and placebo groups.

EffePharm’s R&D Director, Jianjun Yu, emphasised that the clinical trials of Uthever® NMN aim to establish a professional and scientific image, offering confidence to supplement brands and end consumers.

With an expanding list of global partners, including Prohealth Longevity, Do Not Age, Vitanad+, AFEGA Anti-ageing Shop, and Kenay, EffePharm’s Uthever® trademark is gaining recognition and co-branding effects.

Uthever® Global Wellness Partners

EffePharm’s future plans include conducting more consumer-centric NMN function research, as well as exploring the safety and effectiveness of larger NMN doses and related indications. The company is also applying for European Commission authorised Novel Food on NMN to validate its safety and potential benefits further.

Understanding the Endogenous Molecule: NMN

The advancement of Medical Sciences has led to an increase in human lifespan, resulting in a growing interest in exploring anti-ageing compounds. This has brought about an increased interest in endogenous compounds, which are thought to have some potential to help individuals achieve healthy and productive lives even in old age.

NMN is one such endogenous molecule and is involved in nicotinamide adenine dinucleotide (NAD+) biosynthesis, a critical cofactor in cellular processes. Involved in fundamental biological processes, NAD+ depletion is associated with ageing and age-related diseases. This is where supplementation through NMN comes into the picture.

Motivating Factors Behind Conducting NMN Clinical Trials

NMN supplementation has shown potential in preclinical trials for conditions linked to NAD+ deficiency. As a matter of fact, NMN can compensate for NAD+ depletion caused by NAD+ consuming enzymes. Moreover, NMN has fewer adverse side effects compared to other NAD+ precursors.

Preclinical studies have also demonstrated NMN’s pharmacological activities in various health conditions like Cardiac and Cerebral Ischemia, Alzheimer’s disease, diet-and age-induced Type 2 Diabetes, and Obesity — all of which are related to NAD+ deficiency. These promising results in human interventions have further supported the safety of NMN supplementation.

However, limited data exist on its efficacy as an anti-ageing supplement. This study thus aimed to investigate the safety and efficacy of Uthever® NMN, the first branded NMN ingredient. It is a type of NMN supplementation designed to simulate NAD+ metabolism and assess its anti-ageing effects in middle-aged and older adults.

This independent investigation represents EffePharm’s unwavering commitment to offering safe and potent NMN products. These comprehensive clinical trials have also allowed us to gather valuable data and insights into the side effects of NMN on human health, propelling us to the forefront of NMN research and development.

NMN Clinical Study Overview

Our study, titled “A Multicentre, Randomised, Double Blind, Parallel Design, Placebo Controlled Study to Evaluate the Efficacy and Safety of Uthever® (NMN Supplement), an Orally Administered Supplementation in Middle Aged and Older Adults”, was structured as a multi-centre, randomised, double-blind, parallel design, placebo-controlled trial.

The Clinical Trial Design

A well-constructed clinical trial is essential for obtaining reliable and valid data.

The Uthever® trial’s design was dissected as follows to highlight the meticulous structure of this independent clinical trial:

(1) Multi-centre: This denotes that the trial was conducted in multiple locations, a strategy that helps to accumulate a diverse participant base, thereby improving the generalisability of the findings.
(2) Randomised: This process involves randomly assigning participants to either the NMN or placebo group, an approach that minimises biases and ensures any observed effects can be attributed to NMN. Registered in the US under the ID NCT04228640 NMN, our interventional clinical trial aimed to recruit 66 healthy participants between the ages of 40 and 65 years old for a randomised allocation process.
(3) Double-Blind: In a double-blind study, neither the participants nor the investigators know who is receiving NMN or the placebo. This setup further eliminates bias, providing more reliable results.
(4) Parallel Design: This implies that the NMN and placebo groups were studied simultaneously, enhancing the study’s efficiency and allowing for a direct comparison of outcomes. And our intervention model consisted of a parallel assignment to ensure even distribution across the different trial groups.
(5) Placebo-Controlled: This means a group was given a placebo (an inactive substance) to compare the side effects of NMN against the natural course of ageing.

Interpreting Biomarkers in the NMN Clinical Trial

The Uthever® clinical trial employed an array of biomarkers to evaluate NMN’s effectiveness with the primary goal of prevention in mind. Among them, blood cellular NAD+/NADH concentration in serum, physical tests, Body Mass Index (BMI) evaluations, and Homeostatic Model Assessment (HOMA) scoring were also central in assessing NMN’s safety and potential side effects.

The Tripartite Focus of the Uthever® Clinical Trial

Our clinical trial was meticulously designed to scrutinise three primary components of NMN:

(1) A comprehensive safety assessment of NMN
(2) Investigating NMN’s function in anti-ageing
(3) Evaluating NMN’s capacity for energy augmentation and endurance enhancement

These elements were chosen as they form the crux of NMN’s potential benefits, thereby allowing us to evaluate Uthever®’s performance in these critical areas.

The Uthever® Promise: A New Era of Health and Longevity

At EffePharm, we’re not just a private label NMN manufacturer; we aim to carve a path in a new era of health and longevity. Our commitment to quality and safety is evident in the comprehensive clinical trials performed by EffePharm, leading to a range of NMN products that can make a difference in people’s lives.

Elevate your health with Uthever®. Browse our collection of NMN products and make your purchase from our range of wholesale NMN products. Embark on your journey towards a healthier, revitalised life with EffePharm today!

Commitment to Transparency: Registering the Uthever® Clinical Study

We stand by the principle of transparency. Thus, the Uthever® clinical study was registered in both the US and the World Health Organisation’s (WHO) official clinical registry systems. All our study details, procedures, and findings are made public, fostering an open dialogue about our work and its implications for the future of NMN.

Learn more about our study:

doi: 10.3389/fragi.2022.851698
Download full article